BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Deng PB, Jiang J, Hu CP, Cao LM, Li M. Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma: A case report . World J Clin Cases 2022; 10(5): 1580-1585 [PMID: 35211595 DOI: 10.12998/wjcc.v10.i5.1580]
URL: https://www.wjgnet.com/2307-8960/full/v10/i5/1580.htm
Number Citing Articles
1
NivolumabReactions Weekly 2022; 1902(1): 346 doi: 10.1007/s40278-022-13490-0
2
Yujing Zhang, Xiaoyue Wen, Yaqi OuYang, Yingying Hu, Xiangzhi Fang, Jiancheng Zhang, Yin Yuan. Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literatureHeliyon 2024; 10(2): e24380 doi: 10.1016/j.heliyon.2024.e24380
3
Takahisa Niimoto, Takafumi Todaka, Hirofumi Kimura, Shotaro Suzuki, Shumpei Yoshino, Kosuke Hoashi, Hirotaka Yamaguchi. Cytokine release syndrome following COVID-19 infection during treatment with nivolumab for cancer of esophagogastric junction carcinoma: a case report and reviewInternational Journal of Emergency Medicine 2024; 17(1) doi: 10.1186/s12245-024-00691-5
4
Na-Na Tan, Jia Lu, Zhuang-Hong Li, Shi-Ping Zhang, Huan Wang, Jing-Bo Hu, Tian Wang, Jian Xiao, Xiao-Ling Wang, Le Wang. A systematic insight into glycycoumarin as potential IL-8/topo I inhibitor from natural products collected in Taibai mountain based on the combination of in silico and bioassayJournal of Computer-Aided Molecular Design 2025; 39(1) doi: 10.1007/s10822-025-00611-6
5
Ana Geltar, Assist Urska Janzic. Cytokine release syndrome in non- small cell lung cancer patient receiving immune checkpoint inhibitors: A case reportCurrent Problems in Cancer: Case Reports 2025; 17: 100339 doi: 10.1016/j.cpccr.2024.100339